VEGFA and neoplasm: By neutralizing VEGF, bevacizumab disrupts this axis, thereby reducing the recruitment and accumulation of immunosuppressive MDSCs and restoring an effective anti-tumor immune response, as evidenced by an increase in effector T cells (26).